

Supplementary Table 3. Comparison between FFR and other physiologic tests

Study	Year	Number of patients	Stress modality	FFR threshold value	Prevalence of FFR positive CAD (%)	Baseline characteristics					Diagnostic performance			
						Age (years)	Male (%)	DM (%)	HT (%)	DL (%)	Sensitivity (%)	Specificity (%)	Positive LR	Negative LR
FFR vs. Stress ECG														
De Bruyne et al. ¹⁰⁸⁾	1995	60	Exercise	0.72	100	57	95	NR	NR	NR	87	87	6.69	0.15
Pijls et al. ¹⁰⁹⁾	1995	60	Exercise	0.74	100	57	68	NR	NR	NR	NR	NR	NR	NR
Pijls et al. ¹¹⁰⁾	1996	45	Exercise	0.75	47	54	62	NR	NR	NR	76	92	9.18	0.26
FFR vs. Stress Echo														
Bartunek et al. ³⁴⁾	1996	75	Dobutamine	0.75	NR	57	85	NR	NR	NR	76	97	25.33	0.25
Pijls et al. ¹¹⁰⁾	1996	41	Dobutamine	0.75	NR	62	54	NR	NR	NR	53	100	NR	0.47
Jiménez-Navarro et al. ¹¹¹⁾	2001	21	Dobutamine	0.75	30	86	56	NR	NR	NR	43	100	14.88	0.58
Rieber et al. ¹¹²⁾	2004	45	Dobutamine	0.75	NR	60	64	21	69	79	NR	NR	NR	NR
Jung et al. ¹¹³⁾	2008	70	Dobutamine	0.75	NR	64	65	20	76	79	NR	NR	NR	NR
Pattanshetty et al. ¹¹⁴⁾	2015	57	Exercise or dobutamine	0.79	56	61	48	36	77	67	62	39	1.02	0.97
Wu et al. ¹¹⁵⁾	2016	67	Exercise or Dobutamine	0.80	27	60	62	38	78	76	38	96	8.4	0.65
Gurunathan et al. ¹¹⁶⁾	2018	223	Exercise or dobutamine	0.80	22	66	69	43	85	71	68	75	2.72	0.43
Panoulas et al. ¹¹⁷⁾	2018	62	Dobutamine	0.80	38	64	57	32	65	65	100	83.8	6.17	0
FFR vs. SPECT														
Pijls et al. ¹¹⁰⁾	1996	45	Exercise	0.75	47	54	62	NR	NR	NR	57	96	13.71	0.45
Abe et al. ¹¹⁸⁾	2000	46	Exercise	0.75	43	61	85	NR	33	NR	83.3	100	NR	0.17
Caymaz et al. ¹¹⁹⁾	2000	30	Vasodilator	0.75	NR	53	67	NR	NR	NR	91	60	2.28	0.15
Chamuleau et al. ¹²⁰⁾	2001	127	Vasodilator	0.75	NR	61	73	9	33	58	NR	NR	NR	NR
De Bruyne et al. ¹²¹⁾	2001	57	Vasodilator	0.75	82	61	77	7	25	53	82	87	6.31	0.21
Meuwissen et al. ¹²²⁾	2002	151	Vasodilator	0.75	34.4	60	71	14	38	59	69.2	76.7	2.97	0.4
Yanagisawa et al. ¹²³⁾	2002	165	Exercise and/or vasodilator	0.75	NR	61	84	37	54	52	79	73	2.93	0.29
Usui et al. ¹²⁴⁾	2003	167	Exercise and/or vasodilator	0.75	78	62	77	36	57	54	79	79	3.76	0.27
Rieber et al. ¹¹²⁾	2004	43	Dobutamine	0.75	31	64	60	21	69	79	69	87	5.19	0.36

Hacker et al. ¹²⁵⁾	2005	50	Dobutamine	0.75	34	65	64	72	74	82	82	88	6.79	0.20
Samady et al. ¹²⁶⁾	2006	23	Vasodilator	0.75	NR	58	76	22	57	61	88	50	1.76	0.24
Ragosta et al. ¹²⁷⁾	2007	36	Vasodilator	0.75	100	62	75	44	78	NR	59	85	4.03	0.48
Förster et al. ¹²⁸⁾	2009	72	Exercise or vasodilator	0.75	46	67	61	36	74	65	79	74	3.07	0.29
Melikian et al. ¹²⁹⁾	2010	67	Vasodilator	0.80	70	64	63	19	54	51	66	50	1.32	0.69
Jakljević et al. ¹³⁰⁾	2012	103	Vasodilator	0.80	53	66	79	100	88	NR	76	49	1.48	0.49
Jakljević et al. ¹³⁰⁾	2012	183	Vasodilator	0.80	33	65	80	0	72	NR	87	67	2.64	0.19
Mouden et al. ¹³¹⁾	2013	100	Vasodilator	0.75	20	66	64	31	67	65	60	76	2.53	0.53
Sahiner et al. ¹³²⁾	2013	58	Vasodilator	0.75	22	NR	67	41	55	NR	77	51	1.57	0.45
Schaap et al. ¹³³⁾	2013	87	Exercise or vasodilator	0.80	57	63	68	12	63	60	93	79	4.33	0.09
Van de Hoef et al. ¹³⁴⁾	2015	246	Vasodilator	0.80	32	60	69	14	37	59	89	88	7.1	0.13
Pattanshetty et al. ¹¹⁴⁾	2015	32	Vasodilator	0.79	56	61	48	36	77	67	54	40	0.9	1.15
Danad et al. ¹³⁵⁾	2017	206	Vasodilator	0.80	44	58	64	16	46	40	57	94	9.5	0.46
Han et al. ¹³⁶⁾	2018	34	Vasodilator	0.80	34	60	74	27	68	74	67	83	3.94	0.4

Stress CMR vs. FFR (as reference)

Costa et al. ¹³⁷⁾	2007	30	Vasodilator	0.75	32	53	65	23	80	57	93	57	2.14	0.13
Kühl et al. ¹³⁸⁾	2007	28	Vasodilator	0.75	24	61	NR	25	64	32	92	92	11.92	0.09
Watkins et al. ¹³⁹⁾	2009	101	Vasodilator	0.75	40	74	60	16	62	78	91	94	14.79	0.10
Kirschbaum et al. ¹⁴⁰⁾	2011	50	NR	0.80	43	76	64	18	50	64	97	61	2.45	0.05
Lockie et al. ¹⁴¹⁾	2011	38	Vasodilator	0.75	21	79	57	19	NR	NR	79	89	7.13	0.23
Bernhardt et al. ¹⁴²⁾	2012	34	Vasodilator	0.75	37	76	62	15	79	53	87	98	55.58	0.13
Huber et al. ¹⁴³⁾	2012	31	Vasodilator	0.75	27	87	67	23	36	29	88	85	5.98	0.14
Jogiya et al. ¹⁴⁴⁾	2012	53	Vasodilator	0.75	30	77	64	30	66	83	79	92	9.80	0.23
Manka et al. ¹⁴⁵⁾	2012	120	Vasodilator	0.75	NR	75	64	26	73	57	NR	NR	NR	NR
Walcher et al. ¹⁴⁶⁾	2012	36	Vasodilator	0.80	25	75	63	14	78	53	93	90	9.38	0.08
Bettencourt et al. ¹⁴⁷⁾	2012	103	Vasodilator	0.80	24	66	62	39	73	80	80	93	11.70	0.22
Chiribiri et al. ¹⁴⁸⁾	2013	67	Vasodilator	0.80	19	79	NR	25	NR	NR	79	91	8.47	0.23
Groothuis et al. ¹⁰¹⁾	2013	88	Vasodilator	0.75	NR	49	56	12	38	20	NR	NR	NR	NR
Pereira et al. ¹⁴⁹⁾	2013	80	Vasodilator	0.80	NR	67	61	44	73	76	NR	NR	NR	NR
Ebersberger et al. ¹⁵⁰⁾	2013	116	Vasodilator	0.80	NR	61	63	26	60	54	NR	NR	NR	NR
Manka et al. ¹⁵¹⁾	2015	120	Vasodilator	0.75	58	64	75	26	73	57	90	82	5.11	0.12

PET MPI vs. FFR (as reference)

Kajander et al. ⁹³⁾	2011	104	Vasodilator	0.80	24	60	64	13	38	51	95	92	11.26	0.06
Danad et al. ¹⁵²⁾	2013	120	Vasodilator	0.80	66	64	61	21	56	44	71	89	6.53	0.33
Danad et al. ¹⁵³⁾	2014	66	Vasodilator	0.80	46	67	59	17	39	33	87	85	5.72	0.16
Joutsiniemi et al. ¹⁵⁴⁾	2014	104	Vasodilator	0.80	35.6	64	38	13	38	51	95	87	7.06	0.06
Danad et al. ¹³⁵⁾	2017	204	Vasodilator	0.80	44.2	58	64	16	46	40	87	84	5.44	0.15
Stress myocardial CTP vs. FFR (as reference)														
Ko et al. ¹⁵⁵⁾	2012	40	Vasodilator	0.80	53	62	73	5	30	32	95	90	9.5	0.06
Ko et al. ¹⁵⁶⁾	2012	42	Vasodilator	0.80	48	64	65	21	88	69	76	84	4.86	0.29
Bettencourt et al. ¹⁵⁷⁾	2013	101	Vasodilator	0.80	24	67	62	39	72	79	55	95	11.46	0.48
Choo et al. ¹⁵⁸⁾	2013	37	Vasodilator	0.75	36	76	62	24	57	19	93	90	9.68	0.08
Greif et al. ¹⁵⁹⁾	2013	65	Vasodilator	0.80	21	65	70	18	67	48	95	74	3.66	0.07
Huber et al. ¹⁶⁰⁾	2013	32	Vasodilator	0.75	30	66	63	19	34	41	83	88	6.93	0.20
Rossi et al. ¹⁶¹⁾	2014	80	Vasodilator	0.75	27	79	60	20	60	66	88	90	8.98	0.14
Yang et al. ¹⁶²⁾	2017	72	Vasodilator	0.80	39	63	89	32	40	26	79	91	8.78	0.23
Ihdayhid et al. ¹⁶³⁾	2018	46	None	0.80	48	62	76	30	77	87	82	75	2.88	0.37
iFR vs. FFR (as reference)														
FFR/iFR threshold value														
Sen et al. ¹⁶⁴⁾	2012	157	None	0.80/0.83	NR	63	83	34	56	NR	85	91	9.44	0.16
Petraco et al. ¹⁶⁵⁾	2013	312	None	0.80/0.89	NR	62	77	31	62	70	NR	NR	NR	NR
Berry et al. ¹⁶⁶⁾	2013	206	None	0.80/0.83	65	65	71	24	67	62	54	96	13.5	0.48
Park et al. ¹⁶⁷⁾	2013	238	None	0.80/0.90	43	63	68	28	56	63	76	86	5.43	0.28
Jeremias et al. ¹⁶⁸⁾	2014	1593	None	0.80/0.90	NR	63	75	28	NR	NR	79	82	4.39	0.26
Petraco et al. ¹⁶⁹⁾	2014	216	None	0.80/0.90	50	61	75	22	47	73	73	74	2.81	0.36
Petraco et al. ¹⁷⁰⁾	2014	313	None	0.80/0.90	39	67	79	30	74	67	81	79	3.86	0.24
Escaned et al. ¹⁷¹⁾	2015	598	None	0.80/0.89	36	64	69	35	79	NR	73	88	5.98	0.31
Fede et al. ¹⁷²⁾	2015	54	None	0.80/0.89	55	67	76	26	81	91	100	87	7.69	0
Härle et al. ¹⁷³⁾	2015	108	None	0.80/0.89	NR	67	61	NR	NR	NR	80	86	5.65	0.24
Indolfi et al. ¹⁷⁴⁾	2015	82	None	0.80/0.89	30	64	82	17	74	NR	76	84	4.75	0.29
Hennigan et al. ¹⁷⁵⁾	2016	257	None	0.80/0.90	42	NR	69	16	62	68	74	82	4.22	0.31
Kanaji et al. ¹⁷⁶⁾	2016	97	None	0.80/0.89	42	67	79	41	64	55	82	87	6.36	0.21
Cook et al. ¹⁷⁷⁾	2017	301	None	0.80/0.89	36	61	69	22	52	57	83	88	6.92	0.19
Ding et al. ¹⁷⁸⁾	2017	158	None	0.80/0.91	44	64	75	18	67	71	80	82	4.44	0.24
Lee et al. ¹⁷⁹⁾	2017	393	None	0.80/0.90	22	64	77	36	63	69	62	96	14.18	0.39
Meimoun et al. ¹⁸⁰⁾	2017	94	None	0.80/0.88	33	68	80	31	56	56	74	73	2.74	0.36
Scarsini et al. ¹⁸¹⁾	2017	252	None	0.80/0.89	22	80	50	36	86	88	93	87	6.71	0.07

Shiode et al. ¹⁸²⁾	2017	103	None	0.80/0.89	NR	70	75	39	80	59	84	80	4.21	0.2
Emori et al. ¹⁸³⁾	2018	100	None	0.80/0.89	69	70	71	48	73	58	74	74	2.85	0.35
Nobre et al. ¹⁸⁴⁾	2018	326	None	0.80/0.86	NR	67	65	28	83	75	56	79	2.67	0.56
Panoulas et al. ¹¹⁷⁾	2018	62	None	0.80/0.90	34	64	57	32	65	65	73	90	7.56	0.30
Pisters et al. ¹⁸⁵⁾	2018	356	None	0.80/0.89	22	67	69	21	56	37	87	80	4.35	0.16
Spagnoli et al. ¹⁸⁶⁾	2018	40	None	0.80/0.90	NR	66	88	43	83	75	92	75	3.68	0.11
Lee et al. ¹⁸⁷⁾	2019	435	None	0.80/0.89	24	64	78	36	63	71	88	88	7.56	0.14
Mehta et al. ¹⁸⁸⁾	2020	47	None	0.80/0.89	25	65	62	23	57	66	79	89	7.18	0.24
Onishi et al. ¹⁸⁹⁾	2020	323	None	0.80/0.92	33	71	77	53	87	89	74	86	5.29	0.30
QFR vs. FFR (as reference)														
Tu et al. ¹⁹⁰⁾	2016	73	None	0.80	32	66	84	27	44	NA	74	91	8.5	0.3
Yazaki et al. ¹⁹¹⁾	2017	142	None	0.80	31	73	70	29	71	62	89	89	8.14	0.13
Xu et al. ¹⁹²⁾	2017	308	None	0.80	34	61	19	28	60	45	95	92	11.4	0.06
Emori et al. ¹⁹³⁾	2018	75	None	0.80	NA	69	83	45	81	60	92	82	5.1	0.1
Emori et al. ¹⁹³⁾	2018	75	None	0.80	NA	70	72	48	85	61	85	88	7.9	0.1
Westra et al. ¹⁹⁴⁾	2018	172	None	0.80	36	61	67	10	70	NA	86	77	5.4	0.27
Westra et al. ¹⁹⁵⁾	2018	272	None	0.80	33	67	72	29	74	68	87	87	6.58	0.16
Koltowski et al. ¹⁹⁶⁾	2018	268	None	0.80	40	66	72	28	76	55	90	63	2.4	0.2
Ties et al. ¹⁹⁷⁾	2018	128	None	0.80	21	64	60	25	71	73	57	93	8.14	0.46
Zhang et al. ¹⁹⁸⁾	2019	304	None	0.80	NA	NA	NA	NA	NA	NA	92	94	14.7	0.1
Stähli et al. ¹⁹⁹⁾	2019	436	None	0.80	19	72	68	23	88	79	75	98	34.7	0.26
Smit et al. ²⁰⁰⁾	2019	66	None	0.80	29	67	70	100	74	NA	75	95	15	0.26
Smit et al. ²⁰⁰⁾	2019	193	None	0.80	28	67	69	0	68	NA	69	88	5.75	0.35
Hwang et al. ²⁰¹⁾	2019	264	None	0.80	40	61	77	33	50	59	92	90	9.05	0.09
Tanigaki et al. ²⁰²⁾	2019	152	None	0.80	46	69	64	30	65	53	90	82	4.9	0.1
Gutiérrez-Chico et al. ²⁰³⁾	2020	59	None	0.80	35	63	85	39	68	53	91	89	8.6	0.1
Lauri et al. ²⁰⁴⁾	2020	69	None	0.80	39	62	77	26	66	68	86	80	4.29	0.18
Mehta et al. ¹⁸⁶⁾	2020	47	None	0.80	25	65	62	23	57	66	95	86	6.79	0.06
Mejía-Rentería et al. ²⁰⁵⁾	2020	115	None	0.80	40	82	47	NA	NA	NA	84	80	4.2	0.2
Kirigaya et al. ²⁰⁶⁾	2021	95	None	0.80	54	72	79	50	57	64	80	91	8.93	0.22
FFRCT vs. FFR (as reference)														
Koo et al. ²⁰⁷⁾	2011	103	None	0.80	84	63	72	26	65	65	83	67	2.49	0.25
Min et al. ²⁰⁸⁾	2012	252	None	0.80	54	63	71	21	71	80	90	54	1.96	0.19

Nørgaard et al. ²⁰⁹⁾	2014	254	None	0.80	32	64	64	23	69	79	86	79	4.1	0.18
Kruk et al. ²¹⁰⁾	2016	90	None	0.80	43	63	32	14	88	90	76	71	2.62	0.34
Ko et al. ²¹¹⁾	2017	30	None	0.80	47	60	70	30	73.3	80	78	87	5.89	0.26
Yang et al. ¹⁶²⁾	2017	72	None	0.80	39	63	89	32	40	26	87	77	3.78	0.17
Ihdayhid et al. ¹⁶³⁾	2018	46	None	0.80	48	62	76	30	77	87	82	75	2.88	0.37
Driessen et al. ²¹²⁾	2019	157	None	0.80	45	58	64	16	46	40	96	63	2.59	0.06
Ko et al. ²¹³⁾	2019	51	None	0.80	49	62	77	29	77	86	83	84	5.21	0.2
Fujimoto et al. ²¹⁴⁾	2019	75	None	0.80	42	68	68	45	63	68	89	69	2.89	0.16
Tanigaki et al. ²⁰²⁾	2019	152	None	0.80	46	69	64	30	65	53	82	70	2.7	0.3

CAD = coronary artery disease; CMR = cardiac magnetic resonance imaging; CTP = computed tomography perfusion; DL = dyslipidemia; DM = diabetes mellitus; ECG = electrocardiography; Echo = echocardiography; FFR = fractional flow reserve; FFR_{CT} = fractional flow reserve derived from coronary computed tomography angiography; HT = hypertension; iFR = instantaneous wave-free ratio; LR = likelihood ratio; NR = not reported; SPECT = single-photon emission computed tomography; PET MPI = positron emission tomography myocardial perfusion imaging; QFR = quantitative flow ration.